Recent advances in immunotherapy for kidney cancer

Mark W. Ball, Mohamad E Allaf, Charles G. Drake

Research output: Contribution to journalArticle

Abstract

Immunotherapy has been a mainstay of treatment for metastatic renal cell carcinoma (mRCC) since the introduction of high-dose interleukin-2. Recently, improved knowledge of immune regulation and tumor-host immune interactions has led to the development of several novel immunotherapies. Immune checkpoint blockade showed promise in early clinical trials - eventually leading to FDA approval of nivolumab (anti-PD-1) as a second-line treatment for mRCC. Despite encouraging results, PD-1 blockade alone does not achieve durable responses in the majority of patients treated. Improved biomarkers for patient selection, tumor vaccines and combination therapy may augment the efficacy of existing immunotherapies. This review summarizes recent progress in immunotherapy for RCC, focusing on a discussion of emerging agents.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalDiscovery medicine
Volume21
Issue number116
StatePublished - 2016

Fingerprint

Kidney Neoplasms
Immunotherapy
Renal Cell Carcinoma
Active Immunotherapy
Cancer Vaccines
Patient Selection
Interleukin-2
Biomarkers
Clinical Trials
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ball, M. W., Allaf, M. E., & Drake, C. G. (2016). Recent advances in immunotherapy for kidney cancer. Discovery medicine, 21(116), 305-313.

Recent advances in immunotherapy for kidney cancer. / Ball, Mark W.; Allaf, Mohamad E; Drake, Charles G.

In: Discovery medicine, Vol. 21, No. 116, 2016, p. 305-313.

Research output: Contribution to journalArticle

Ball, MW, Allaf, ME & Drake, CG 2016, 'Recent advances in immunotherapy for kidney cancer', Discovery medicine, vol. 21, no. 116, pp. 305-313.
Ball, Mark W. ; Allaf, Mohamad E ; Drake, Charles G. / Recent advances in immunotherapy for kidney cancer. In: Discovery medicine. 2016 ; Vol. 21, No. 116. pp. 305-313.
@article{e5de32448e654465ab4e36a6bfffdb12,
title = "Recent advances in immunotherapy for kidney cancer",
abstract = "Immunotherapy has been a mainstay of treatment for metastatic renal cell carcinoma (mRCC) since the introduction of high-dose interleukin-2. Recently, improved knowledge of immune regulation and tumor-host immune interactions has led to the development of several novel immunotherapies. Immune checkpoint blockade showed promise in early clinical trials - eventually leading to FDA approval of nivolumab (anti-PD-1) as a second-line treatment for mRCC. Despite encouraging results, PD-1 blockade alone does not achieve durable responses in the majority of patients treated. Improved biomarkers for patient selection, tumor vaccines and combination therapy may augment the efficacy of existing immunotherapies. This review summarizes recent progress in immunotherapy for RCC, focusing on a discussion of emerging agents.",
author = "Ball, {Mark W.} and Allaf, {Mohamad E} and Drake, {Charles G.}",
year = "2016",
language = "English (US)",
volume = "21",
pages = "305--313",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "116",

}

TY - JOUR

T1 - Recent advances in immunotherapy for kidney cancer

AU - Ball, Mark W.

AU - Allaf, Mohamad E

AU - Drake, Charles G.

PY - 2016

Y1 - 2016

N2 - Immunotherapy has been a mainstay of treatment for metastatic renal cell carcinoma (mRCC) since the introduction of high-dose interleukin-2. Recently, improved knowledge of immune regulation and tumor-host immune interactions has led to the development of several novel immunotherapies. Immune checkpoint blockade showed promise in early clinical trials - eventually leading to FDA approval of nivolumab (anti-PD-1) as a second-line treatment for mRCC. Despite encouraging results, PD-1 blockade alone does not achieve durable responses in the majority of patients treated. Improved biomarkers for patient selection, tumor vaccines and combination therapy may augment the efficacy of existing immunotherapies. This review summarizes recent progress in immunotherapy for RCC, focusing on a discussion of emerging agents.

AB - Immunotherapy has been a mainstay of treatment for metastatic renal cell carcinoma (mRCC) since the introduction of high-dose interleukin-2. Recently, improved knowledge of immune regulation and tumor-host immune interactions has led to the development of several novel immunotherapies. Immune checkpoint blockade showed promise in early clinical trials - eventually leading to FDA approval of nivolumab (anti-PD-1) as a second-line treatment for mRCC. Despite encouraging results, PD-1 blockade alone does not achieve durable responses in the majority of patients treated. Improved biomarkers for patient selection, tumor vaccines and combination therapy may augment the efficacy of existing immunotherapies. This review summarizes recent progress in immunotherapy for RCC, focusing on a discussion of emerging agents.

UR - http://www.scopus.com/inward/record.url?scp=85007290529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007290529&partnerID=8YFLogxK

M3 - Article

C2 - 27232516

AN - SCOPUS:85007290529

VL - 21

SP - 305

EP - 313

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 116

ER -